The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Comments

No comments yet. Be the first!